Abstract
Purpose
In the past decade, there has been an increase in the development and use of oral anti-cancer medications (OAMs), especially for breast cancer–the most prevalent cancer in women. However, adherence rates for OAMs are often suboptimal, leading to lower survival rate, increased risk of recurrence, and higher healthcare costs. Our goal was to identify potentially modifiable psychosocial facilitators and barriers that may be targeted to increase OAM adherence for breast cancer patients.
Methods
We systematically searched PubMed for studies published in the U.S. by June 15, 2016 that addressed the following: (1) OAMs for breast cancer; (2) medication adherence; and (3) at least one psychosocial aspect of adherence.
Results
Of the 1752 papers screened, 21 articles were included and analyzed. The most commonly reported motivators for adherence are patient-provider relationships (n = 11 studied, 82% reported significant association) and positive views and beliefs of medication (n = 9 studied, 89% reported significant association). We also identified consistent evidence of the impact of depression and emotions, perception of illness, concern of side effects, self-efficacy in medication management and decision making, knowledge of medication, and social support on OAM adherence.
Conclusions
Compared to traditional demographic, system, and clinical-related factors that have been well documented in the literature but are not easily changed, these cognitive, psychological, and interpersonal factors are more amendable via intervention and therefore could generate greater benefit in improving patient compliance and health outcomes. As OAMs shift treatment administration responsibility onto patients, continuous provider communication and education on illness and regimen are the keys to supporting patients’ medication behavior.
Similar content being viewed by others
References
Foulon V, Schoffski P, Wolter P (2011) Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clin Belg 66(2):85–96
Weingart SN et al (2008) NCCN Task Force Report: Oral chemotherapy. J Natl Compr Cancer Netw 6(Suppl 3):S1–S14
Fallowfield L et al (2006) Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 17(2):205–210
Liu G et al (1997) Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15(1):110–115
Mazzoni E et al (2010) 22 Adherence to and persistence with an oral metronomic chemotherapy with capecitabine in heavily pretreated metastatic breast cancer (MBC) patients. Cancer Treat Rev 36:S101
Benjamin L et al (2012) Physicians’ preferences for prescribing oral and intravenous anticancer drugs: a discrete choice experiment. Eur J Cancer 48(6):912–920
Waterhouse DM et al (1993) Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 11(6):1189–1197
Ruddy K, Mayer E, Partridge A (2009) Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 59(1):56–66
Murphy CC et al (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478
von Mehren M, Widmer N (2011) Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 37(4):291–299
Breast cancer statistics. [Web] 2016 March 23, 2016; Available from: https://www.cdc.gov/cancer/breast/statistics/
McCowan C et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99(11):1763–1768
Makubate B et al (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7):1515–1524
Hershman DL et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537
Wood L (2012) A review on adherence management in patients on oral cancer therapies. Eur J Oncol Nurs 16(4):432–438
Partridge AH et al (2002) Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94(9):652–661
Culos-Reed SN et al (2000) Predictors of adherence to behavior change interventions in the elderly. Controll Clin Trials 21(5):S200–S205
Van Liew JR, Christensen AJ, de Moor JS (2014) Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research. J Cancer Surviv 8(3):521–531
Vrijens B et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73(5):691–705
Barillet M et al (2015) Oral antineoplastic agents: how do we care about adherence? Br J Clin Pharmacol 80(6):1289–1302
Greer JA et al (2016) A systematic review of adherence to oral antineoplastic therapies. Oncologist 21(3):354–376
Verbrugghe M et al (2013) Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treat Rev 39(6):610–621
van Londen GJ et al (2014) Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms. Oncol Nurs Forum 41(6):660–668
Rust C, Davis C (2011) Health literacy and medication adherence in underserved African-american breast cancer survivors: a qualitative study. Soc Work Health Care 50(9):739–761
Wells KJ et al (2016) Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer 24:4123–4130
Neugut AI et al (2016) A prospective cohort study of early discontinuation of adjuvant chemotherapy in women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 158:127–138
Lebovits AH et al (1990) Patient noncompliance with self-administered chemotherapy. Cancer 65(1):17–22
Bhatta SS et al (2013) Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer. Springerplus 2:356
Jacob Arriola KR et al (2014) Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients. Patient Educ Couns 95(1):98–103
Fink AK et al (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor–positive breast cancer. J Clin Oncol 22(16):3309–3315
Kirk MC, Hudis CA (2008) Insight into barriers against optimal adherence to oral hormonal therapy in women with breast cancer. Clin Breast Cancer 8(2):155–161
Friese CR et al (2013) Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat 138(3):931–939
Lash TL et al (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99(2):215–220
Hershman DL et al (2016) Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the breast cancer quality of care study (BQUAL). Breast Cancer Res Treat 157(1):133–143
Walker HE et al (2016) Perceptions, attributions, and emotions toward endocrine therapy in young women with breast cancer. J Adolesc Young Adult Oncol 5(1):16–23
Rust CF, Davis C, Moore MR (2015) Medication adherence skills training for African–American breast cancer survivors: the effects on health literacy, medication adherence, and self-efficacy. Soc Work Health Care 54(1):33–46
Manning M, Bettencourt BA (2011) Depression and medication adherence among breast cancer survivors: bridging the gap with the theory of planned behaviour. Psychol Health 26(9):1173–1187
Kimmick G et al (2015) Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. Breast 24(5):630–636
Liu Y et al (2013) Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast Cancer Res Treat 137(3):829–836
Kahn KL et al (2007) Patient centered experiences in breast cancer: predicting long-term adherence to tamoxifen use. Med Care 45(5):431–439
Llarena NC et al (2015) Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst 107(10):dvj202
Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19(2):322–328
Bender CM et al (2014) Influence of patient and treatment factors on adherence to adjuvant endocrine therapy in breast cancer. Oncol Nurs Forum 41(3):274–285
Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497
Malbasa T, Kodish E, Santacroce SJ (2007) Adolescent adherence to oral therapy for leukemia: a focus group study. J Pediatr Oncol Nurs 24(3):139–151
Richardson JL et al (1987) Path model of multidimensional compliance with cancer therapy. Health Psychol 6(3):183–207
Spoelstra SL et al (2016) Proof of concept of a mobile health short message service text message intervention that promotes adherence to oral anticancer agent medications: a randomized controlled trial. Telemed J E Health 22(6):497–506
Tebbi CK et al (1988) The role of parent-adolescent concordance in compliance with cancer chemotherapy. Adolescence 23(91):599–611
Stirratt MJ et al (2015) Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med 5(4):470–482
Zullig LL et al. (2017) Medication adherence: a practical measurement selection guide using case studies. Patient Education and Couns
Blay JY, Rutkowski P (2014) Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. Cancer Treat Rev 40(2):242–247
Kondryn HJ et al (2011) Treatment non-adherence in teenage and young adult patients with cancer. Lancet Oncol 12(1):100–108
Kanters S et al (2017) Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. Lancet HIV 4(1):e31–e40
Viswanathan M et al (2012) Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 157(11):785–795
Mathes T et al (2014) Adherence enhancing interventions for oral anticancer agents: a systematic review. Cancer Treat Rev 40(1):102–108
Bestvina CM, Zullig LL, Zafar SY (2014) The implications of out-of-pocket cost of cancer treatment in the USA: a critical appraisal of the literature. Future Oncol 10(14):2189–2199
Acknowledgement
Dr. Bosworth is supported by the VA Research Career Scientist Award (RCS 08-027); and Dr. Zullig is supported by the VA Health Services Research and Development (HSR&D) Career Development Award (CDA 13-025). The project is partially funded by Duke University Bass Connections for interdisciplinary research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Lin, C., Clark, R., Tu, P. et al. Breast cancer oral anti-cancer medication adherence: a systematic review of psychosocial motivators and barriers. Breast Cancer Res Treat 165, 247–260 (2017). https://doi.org/10.1007/s10549-017-4317-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-017-4317-2